Numab Therapeutics

Immuno-Oncology and Inflammation


HBM contact: Dr Matthias Fehr, Dr Asun Monfort

Company status: private

Numab applies its proprietary antibody discovery and engineering technology to generate highly potent and stable antibody Fv fragments, which serve as building blocks to create mono- or multispecific antibody fragment-based therapeutics with tailored pharmacokinetic properties.
The company has created a broad proprietary pipeline of compounds in immune-oncology and the field of inflammation and has entered into several partnerships with pharmaceutical companies.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171